about
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.Regional hyperthermia for high-risk soft tissue sarcoma treatment: present status and next questions.Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.Concomitant trimodality therapy of re-irradiation, chemotherapy and regional hyperthermia for a pretreated inoperable sarcoma recurrence.VEGFR2 predicts decreased patients survival in soft tissue sarcomas.Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO).Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma - Authors' reply.Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.[Soft-tissue sarcoma: recent developments].Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upSoft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[Operative therapy of abdominal and retroperitoneal sarcoma]Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case reportRegional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma-ReplyGastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P50
Q35214578-CF573259-7929-422A-8A83-CCDCAF7B5C3FQ35887964-F702AF29-D292-4999-A7B9-98FDE1C0BFA3Q36497626-D5BB2B16-87D8-47E0-94B9-CE67C6C1A93EQ37222064-982C8C5E-65D2-4EBC-AD2D-5D2B7DD96B2CQ38709493-46DA8B43-CD7C-45A5-B9ED-32B472AFD645Q38907791-3743849E-E0C0-4357-8FFA-00ECAFEA23A7Q39002826-F6017450-36FA-4E56-8591-940587013027Q39018240-F59B9247-B20C-4698-BF65-F2F33A603B3AQ39191536-C3A116E4-E34F-4460-B03A-9CDDF024C430Q41460399-B0B886B0-0F2D-4A2B-8ECC-D83F61B0B17DQ41595940-DB826318-57CD-4594-AB67-DE42BCE4A393Q49952075-8677956F-1D12-447C-BDD4-08DA605BFD07Q50060027-CD3D8A11-5F7B-485F-BD2A-95601F053189Q53025798-4070C3AF-0424-4890-8298-7F728D3D0865Q53148283-DDC73335-148B-4DA7-A7CC-5AA2564D2ED9Q56381047-992C737D-AE25-46DC-A07B-F8A59E588B0EQ56381058-587E95BA-2A59-40AB-B978-F01710CA8E3AQ87690114-743A3C99-D94B-47E4-BEE6-27BE27CF034AQ92522565-E3C23D1A-4D9D-4609-AB7B-0930EDCFFE7FQ93390779-731B75FA-F114-44C5-A80A-2054BCF1F7C1Q95784829-9882C0F8-CA30-47EF-B270-8AFA71619C42
P50
description
investigador
@es
researcher
@en
name
Rolf D Issels
@en
type
label
Rolf D Issels
@en
prefLabel
Rolf D Issels
@en
P31
P496
0000-0002-3494-6561